MX346024B - Optimización de solubilidad de inmuno-aglutinantes. - Google Patents

Optimización de solubilidad de inmuno-aglutinantes.

Info

Publication number
MX346024B
MX346024B MX2013011865A MX2013011865A MX346024B MX 346024 B MX346024 B MX 346024B MX 2013011865 A MX2013011865 A MX 2013011865A MX 2013011865 A MX2013011865 A MX 2013011865A MX 346024 B MX346024 B MX 346024B
Authority
MX
Mexico
Prior art keywords
immunobinders
solubility
scfvs
engineering
provides
Prior art date
Application number
MX2013011865A
Other languages
English (en)
Inventor
Borras Leonardo
Urech David
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346024(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of MX346024B publication Critical patent/MX346024B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un método para mejorar la solubilidad de un inmuno-aglutinante, el inmuno-aglutinante comprende una región variable de cadena pesada (VH) , o fragmento del mismo, el método comprende: mutar los residuos de aminoácidos en las posiciones 12, 103,y 144 (de acuerdo con la convención de numeración AHo), en donde la mutación comprende la sustitución del aminoácido en la posición de aminoácidos identificada con (a) Serina (S) en la posición 12 de aminoácidos de cadena pesada; (b) Serina (S) o Treonina (T) en la posición 103 de aminoácidos de cadena pesada y; (c) Serina (S) o Treonina (T) en la posición 144 de aminoácidos de cadena pesada.
MX2013011865A 2008-06-25 2009-06-25 Optimización de solubilidad de inmuno-aglutinantes. MX346024B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7569208P 2008-06-25 2008-06-25
PCT/CH2009/000221 WO2009155725A1 (en) 2008-06-25 2009-06-25 Solubility optimization of immunobinders

Publications (1)

Publication Number Publication Date
MX346024B true MX346024B (es) 2017-03-02

Family

ID=41228195

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011865A MX346024B (es) 2008-06-25 2009-06-25 Optimización de solubilidad de inmuno-aglutinantes.
MX2011000074A MX2011000074A (es) 2008-06-25 2009-06-25 Optimizacion de solubilidad de inmuno-aglutinantes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000074A MX2011000074A (es) 2008-06-25 2009-06-25 Optimizacion de solubilidad de inmuno-aglutinantes.

Country Status (21)

Country Link
US (3) US9556265B2 (es)
EP (2) EP2307455B1 (es)
JP (3) JP5745720B2 (es)
KR (2) KR101650165B1 (es)
CN (2) CN102076715B (es)
AU (1) AU2009264566B2 (es)
BR (1) BRPI0914666A2 (es)
CA (1) CA2728829C (es)
CY (2) CY1119626T1 (es)
DK (2) DK3241843T3 (es)
ES (2) ES2629345T3 (es)
HR (2) HRP20171250T1 (es)
HU (2) HUE034827T2 (es)
LT (2) LT2307455T (es)
MX (2) MX346024B (es)
PL (2) PL2307455T3 (es)
PT (2) PT2307455T (es)
RU (3) RU2514658C2 (es)
SI (2) SI2307455T1 (es)
WO (1) WO2009155725A1 (es)
ZA (1) ZA201008595B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2677003T3 (es) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
KR101650165B1 (ko) 2008-06-25 2016-08-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
AU2009264565C1 (en) 2008-06-25 2022-01-27 Novartis Ag Stable and soluble antibodies inhibiting VEGF
PT3444274T (pt) 2008-06-25 2021-03-17 Novartis Ag Anticorpos que inibem tnf estáveis e solúveis
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
CN109293768A (zh) 2009-12-23 2019-02-01 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 减少免疫原性的方法
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US20130310281A1 (en) * 2011-02-02 2013-11-21 Glaxo Group Limited Novel antigen binding proteins
EP3750917A1 (en) 2012-11-05 2020-12-16 Delenex Therapeutics AG Binding members to il-1 beta
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
AU2013378628A1 (en) * 2013-02-15 2015-06-11 Esbatech - A Novartis Company Llc Acceptor framework for CDR grafting
JP2016506752A (ja) * 2013-02-20 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
DK3042205T3 (da) * 2013-09-06 2020-03-02 Hoffmann La Roche Fremgangsmåde til forbedring af antistofstabilitet
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
HUE039540T2 (hu) * 2015-10-21 2019-01-28 Trinseo Europe Gmbh Elasztomer polimerek funkcionalizálása során történõ alkalmazásra szolgáló aminoszilán-funkcionalizált diének
BR112018067698A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag células modificadas para imunoterapia
AU2022219517A1 (en) 2021-02-12 2023-07-13 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
US20220340894A1 (en) 2021-03-09 2022-10-27 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
CA3210289A1 (en) 2021-03-09 2022-09-15 Anna Maria SOBIERAJ Mage-a4 peptide-mhc antigen binding proteins
WO2023110918A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
CN1300173C (zh) 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK0985039T3 (da) 1997-06-12 2008-06-09 Novartis Int Pharm Ltd Kunstige antistof-polypeptider
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DK1974747T3 (da) 1998-08-11 2012-09-17 Biogen Idec Inc Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
CA2396534C (en) 1999-12-28 2012-10-02 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
AU2001239857B9 (en) * 2000-02-25 2006-07-27 Duke University Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
US6905608B2 (en) 2002-01-22 2005-06-14 Exergy Technologies Corporation Advanced electrodeionization for fluid recycling
CN102093477B (zh) 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
KR20170073698A (ko) * 2003-05-30 2017-06-28 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
DK1773872T3 (en) 2004-05-21 2017-05-08 Uab Res Found VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
BRPI0611765B1 (pt) 2005-06-07 2022-09-27 Esbatech Ag Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
EP3093026B1 (en) 2006-07-10 2020-07-01 ESBATech, an Alcon Biomedical Research Unit LLC Scfv antibodies which pass epithelial and/or endothelial layers
CN103275216B (zh) 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
CN102838673B (zh) 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
KR101650165B1 (ko) 2008-06-25 2016-08-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화

Also Published As

Publication number Publication date
JP2011525496A (ja) 2011-09-22
US11046757B2 (en) 2021-06-29
RU2514658C2 (ru) 2014-04-27
CN105418763A (zh) 2016-03-23
BRPI0914666A2 (pt) 2015-10-20
HUE034827T2 (en) 2018-03-28
ZA201008595B (en) 2012-02-29
MX2011000074A (es) 2011-02-24
AU2009264566B2 (en) 2014-05-08
SI3241843T1 (sl) 2021-11-30
RU2011102548A (ru) 2012-07-27
US20110268728A1 (en) 2011-11-03
PL2307455T3 (pl) 2017-09-29
US20190169284A1 (en) 2019-06-06
ES2629345T3 (es) 2017-08-08
KR101650165B1 (ko) 2016-08-22
RU2653441C2 (ru) 2018-05-08
EP3241843A1 (en) 2017-11-08
CA2728829C (en) 2018-01-02
US9556265B2 (en) 2017-01-31
CN102076715A (zh) 2011-05-25
CY1124644T1 (el) 2022-07-22
JP2016128517A (ja) 2016-07-14
ES2884117T3 (es) 2021-12-10
EP3241843B1 (en) 2021-07-28
EP2307455B1 (en) 2017-03-22
HRP20171250T1 (hr) 2017-10-20
JP2014111667A (ja) 2014-06-19
DK3241843T3 (da) 2021-09-06
AU2009264566A1 (en) 2009-12-30
HUE056090T2 (hu) 2022-01-28
CN102076715B (zh) 2018-06-19
PT2307455T (pt) 2017-07-03
WO2009155725A1 (en) 2009-12-30
PT3241843T (pt) 2021-09-10
DK2307455T3 (en) 2017-07-10
JP5745720B2 (ja) 2015-07-08
CA2728829A1 (en) 2009-12-30
KR101790567B1 (ko) 2017-10-26
HRP20211356T1 (hr) 2021-11-26
US20170096482A1 (en) 2017-04-06
LT2307455T (lt) 2017-06-26
RU2018112257A (ru) 2019-10-09
EP2307455A1 (en) 2011-04-13
KR20110022714A (ko) 2011-03-07
RU2014104577A (ru) 2015-08-20
KR20160083129A (ko) 2016-07-11
US10221237B2 (en) 2019-03-05
SI2307455T1 (sl) 2017-07-31
LT3241843T (lt) 2021-09-27
PL3241843T3 (pl) 2021-12-27
CY1119626T1 (el) 2018-04-04

Similar Documents

Publication Publication Date Title
MX346024B (es) Optimización de solubilidad de inmuno-aglutinantes.
MX2009013328A (es) Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
CY1126083T1 (el) Μοντελα τρωκτικων και θεραπευτικα μορια
MX2009013327A (es) Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple.
WO2009004066A3 (en) Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
NZ717213A (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2721753T3 (es) Anticuerpos contra IL-6 y usos de los mismos
IN2009DN05758A (es)
GEP20125517B (en) Humanized monoclonical antibodies to hepatocyte growth factor
ATE500327T1 (de) Verfahren und zusammensetzungen für ethanolproduzierende cyanobakterien
AR083747A1 (es) Anticuerpos anti-il-23
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
AR060417A1 (es) Anticuerpos dirigidos contra receptor del activador de plasminogeno tipo uroquinasa (upar) y usos de dichos anticuerpos
NZ626269A (en) Anti-phf-tau antibodies and their uses
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
GB201108236D0 (en) Method
MY152068A (en) Bispecific anti-her antibodies
RS54627B1 (en) CANCER EXPRESSION ANTIBODIES THAT EXPLAIN CLAUDINE 6
GB2458430A (en) Method for generating a reference signal sequence using grouping
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
CL2010000470A1 (es) Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo.
WO2012047583A3 (en) Antibodies binding human collagen ii
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.